retatrutide triple agonist obesity trial ⭐️topline results from TRIUMPH-1, a Phase 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon hormone receptor agonist, in adults with or “overweight” retatrutide obesity triple hormone receptor

Since enzymes quickly break down natural GLP-1, GLP-1 RA drugs extend the effects of the natural hormone

Commonly reported side effects in the Phase 2 trial included: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite Abdominal discomfort or bloating Eructation (belching) The majority of participants who discontinued treatment did so due to gastrointestinal side effects, underscoring the importance of the slow titration schedule used in trials

At one year, patients on Saxenda had an average placebo-corrected weight loss of 12 pounds or about 6% of body weight

Metabolic and Endocrine Risks Hypoglycemia (CRITICAL RISK): The most serious acute risk is low blood sugar

Global burden of metabolic dysfunction-associated steatotic liver disease